• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心脏保护剂(+)-1,2-双(3,5-二氧代哌嗪基-1-基)丙烷水解激活的药效学

Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.

作者信息

Hasinoff B B

机构信息

Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada.

出版信息

J Pharm Sci. 1994 Jan;83(1):64-7. doi: 10.1002/jps.2600830115.

DOI:10.1002/jps.2600830115
PMID:8138912
Abstract

The hydrolysis of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] to its presumed active form under conditions of physiologic pH and temperature were followed by HPLC chromatography. Successful chromatography of all of the hydrolysis products required the use of EDTA in the aqueous eluant to prevent metals in the HPLC flow system from binding to the strongly metal ion-binding product ADR-925. The kinetics of the hydrolysis was followed to approximately 200 h. The ring closest to the methyl group on ICRF-187 was observed to open at about twice the rate of the other ring. This product accumulates in the reaction mixture not only because it is produced more quickly but also because it decays more slowly. ICRF-187 is lost from the reaction mixture with a half-life of 9.3 h, whereas the final hydrolysis product ADR-925 is produced with a half-life of 23.0 h. Rate constants for ring opening to one-ring and two-ring opened hydrolysis products were obtained with a reaction scheme that assumed parallel and consecutive first-order reactions for these steps.

摘要

在生理pH值和温度条件下,采用高效液相色谱法跟踪心脏保护剂ICRF - 187 [(+)-1,2 - 双(3,5 - 二氧代哌嗪基-1 - 基)丙烷]水解为其假定活性形式的过程。要成功分离所有水解产物,需要在水性洗脱液中使用乙二胺四乙酸(EDTA),以防止高效液相色谱流动系统中的金属与强金属离子结合产物ADR - 925结合。跟踪水解动力学约200小时。观察到ICRF - 187上最靠近甲基的环的开环速率约为另一个环的两倍。该产物在反应混合物中积累,不仅是因为它产生得更快,还因为它衰变得更慢。ICRF - 187从反应混合物中消失的半衰期为9.3小时,而最终水解产物ADR - 925的产生半衰期为23.0小时。通过一个反应方案获得了开环生成单环和双环开环水解产物的速率常数,该方案假设这些步骤为平行和连续的一级反应。

相似文献

1
Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.心脏保护剂(+)-1,2-双(3,5-二氧代哌嗪基-1-基)丙烷水解激活的药效学
J Pharm Sci. 1994 Jan;83(1):64-7. doi: 10.1002/jps.2600830115.
2
Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.
Drug Metab Dispos. 1993 Sep-Oct;21(5):883-8.
3
The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.
Drug Metab Dispos. 1991 Jan-Feb;19(1):74-80.
4
The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).阿霉素的铁(III)和铜(II)配合物可促进心脏保护剂ICRF - 187((+)-1,2 - 双(3,5 - 二氧代哌嗪基 - 1 - 基)丙烷)的水解。
Agents Actions. 1990 Mar;29(3-4):374-81. doi: 10.1007/BF01966470.
5
The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925.心脏保护剂ICRF-187 [(+)-1,2-双(3,5-二氧代哌嗪基-1-基)丙烷]及其水解产物ADR-925对转铁蛋白、铁蛋白和铜蓝蛋白中金属离子的去除作用
Agents Actions. 1993 May;39(1-2):72-81. doi: 10.1007/BF01975717.
6
The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
Drug Metab Dispos. 1990 May-Jun;18(3):344-9.
7
Is ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] unusually reactive for an imide?ICRF - 187 [(+)-1,2 - 双(3,5 - 二氧代哌嗪 - 1 - 基)丙烷]作为一种酰亚胺,其反应活性是否异常?
Pharm Res. 1992 Aug;9(8):1076-82. doi: 10.1023/a:1015818931062.
8
The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.心脏保护剂ICRF - 187[(+)-1,2 - 双(3,5 - 二氧代哌嗪基 - 1 - 基)丙烷];其水解产物(ICRF - 198);以及其他螯合剂与阿霉素的铁(III)和铜(II)配合物的相互作用。
Agents Actions. 1989 Mar;26(3-4):378-85. doi: 10.1007/BF01967305.
9
Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).二氢乳清酸酶催化心脏保护药物右雷佐生(ICRF-187)水解中间体的开环反应。
Drug Metab Dispos. 2002 Dec;30(12):1431-5. doi: 10.1124/dmd.30.12.1431.
10
Characterization of the aqueous decomposition products of (+)1,2-bis(3,5-dioxopiperazinyl-1-yl)-propane (ICRF-187) by liquid chromatographic and mass spectral analysis.通过液相色谱和质谱分析对(+)1,2 - 双(3,5 - 二氧代哌嗪 - 1 - 基)丙烷(ICRF - 187)的水性分解产物进行表征。
J Pharm Sci. 1991 Apr;80(4):338-40. doi: 10.1002/jps.2600800411.

引用本文的文献

1
UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study.UHPLC-MS/MS 法分析 sobuzoxane、其活性形式 ICRF-154 和代谢物 EDTA-二酰胺及其在生物活化研究中的应用。
Sci Rep. 2019 Mar 14;9(1):4524. doi: 10.1038/s41598-019-40928-5.
2
The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B.右丙亚胺(Cardioxane)的心脏保护作用与通过自组装螯合聚(ADP - 核糖)一致,而非拓扑异构酶2B的耗竭。
Ecancermedicalscience. 2018 Dec 20;12:889. doi: 10.3332/ecancer.2018.889. eCollection 2018.
3
Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs.
右丙亚胺对猪心肌梗死再灌注急性期无保护作用。
PLoS One. 2016 Dec 21;11(12):e0168541. doi: 10.1371/journal.pone.0168541. eCollection 2016.
4
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.蒽环类药物心脏毒性的氧化应激、氧化还原信号和金属螯合作用及药理学心脏保护作用。
Antioxid Redox Signal. 2013 Mar 10;18(8):899-929. doi: 10.1089/ars.2012.4795. Epub 2012 Oct 12.
5
Scavenging effects of dexrazoxane on free radicals.地塞米松磷酸钠对自由基的清除作用。
J Clin Biochem Nutr. 2010 Nov;47(3):238-45. doi: 10.3164/jcbn.10-64. Epub 2010 Oct 29.
6
Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.右丙亚胺预处理可保护去表皮大鼠心脏小梁免受阿霉素诱导的延迟性横桥动力学损伤。
Br J Pharmacol. 2002 Apr;135(7):1707-14. doi: 10.1038/sj.bjp.0704621.
7
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.右丙亚胺。关于其在接受蒽环类药物化疗患者中作为心脏保护剂应用的综述。
Drugs. 1998 Sep;56(3):385-403. doi: 10.2165/00003495-199856030-00009.
8
The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.心脏保护剂ICRF-187(右丙亚胺)的单环开环水解产物中间体可从铁-蒽环类复合物中置换出铁。
Agents Actions. 1993 Sep;40(1-2):86-95. doi: 10.1007/BF01976756.